A groundbreaking drug developed in Western Australia to combat a disease that can lead to strokes and heart attacks could have a significant impact on the $14.3 billion annual cost of cardiovascular disease in Australia.

Atherosclerosis is a condition that results in the accumulation of cholesterol and other fats in the arteries, leading to narrowing of the vessels and an increased risk of blockages, strokes, heart attacks, and other complications.

While current treatments for atherosclerosis focus on managing risk factors, they do not provide a cure. However, a new drug called ATH01, developed by Atherid Therapeutics, aims to address this gap and offer a potential cure.

Founded by researchers from the Harry Perkins Institute of Medical Research, Associate Professor Juliana Hamzah and Professor Shirley Jansen, Atherid Therapeutics has secured $750,000 in funding to expedite the production of ATH01.

Professor Hamzah, the inventor of the drug, identified a protein that binds to cells in the arteries, stores cholesterol and fats, and aids in clearing the accumulated fats. ATH01 targets this root cause by breaking down the build-up of lipids, providing a transformative solution that combines two powerful molecules.

Professor Jansen highlighted the precise targeting of the drug, ensuring it reaches the affected areas in the arterial system. If successful, ATH01 could potentially improve the lives of millions by reducing the burden of cardiovascular disease.

After a decade of research, the team is now ready to advance to human trials following the successful production of the drug's initial stage. The drug has the potential to significantly decrease the impact of cardiovascular disease, which claims over 18 million lives globally each year, with more than 42,000 in Australia alone.

With over 57,000 heart attacks, 38,000 strokes, and 8,000 amputations occurring annually in Australia, the need for innovative treatments like ATH01 is crucial. Professor Hamzah emphasized the journey from a high-risk idea to a potentially life-changing therapy that could revolutionize the treatment of atherosclerosis.

Professor Peter Leedman, the director of the Harry Perkins Institute, expressed excitement about the progress made in developing this groundbreaking drug and its potential to transform clinical research in combating atherosclerosis.